Clinical Pharmacy and Biopharmacy- Scholarly Publications

Permanent URI for this collection

https://ir.unilag.edu.ng/handle/123456789/3747

Browse

Browsing Clinical Pharmacy and Biopharmacy- Scholarly Publications by Subject "Analgesic"

Now showing 1 - 2 of 2
  • Item
    Restricted
    Awareness and pattern of pentazocine use in patients with sickle cell disease in two sickle cell clinics in Lagos state, Nigeria
    (Nigerian Journal of Pharmacy, 2021) Ayeni, F.A; Ogbo, P.U; Onwuchuluba, E.E; Haruna, M.R
    Background: Sickle cell disease (SCD) is a genetic disorder which leads to acute or chronic pain and thus requires the use of opioids and non-opioid medications. Pentazocine is a commonly used opioid among sickle cell patients for the management of moderate to severe pain. Patients understanding of the purpose and pattern of pentazocine use will encourage rational use and discourage misuse, especially outside the hospital setting. This study was set to assess the awareness and pattern of use of pentazocine among SCD patients. Methods: The study was a cross-sectional, descriptive, questionnaire-based study conducted in two sickle cell clinics in Lagos State. A pretested questionnaire based on extant literature was employed to obtain patients sociodemographic data. Data was also obtained regarding prescribed medications, as well as patients' awareness and use of pentazocine. These data were analyzed using descriptive and inferential statistics in SPSS, version 21.0. Results: Of the eighty respondents interviewed, most, 68 (85.0%) were single, 42 (52.5%) were females, and 50 (62.5%) had tertiary education. Mean age was 26.49 8.16 years. Commonly prescribed painkillers were Ibuprofen (31.4%), Paracetamol (28.9%), Diclofenac (26.9%) and Pentazocine (20.0%). Less than half, 32 (40%) were aware of pentazocine use in managing moderate to severe pain. Of these, 16 (50%) used it outside the clinic. 56.3% of those who used pentazocine outside the clinics used it because they had “unbearable pain”. There was a significant association between age and Pentazocine awareness (p = 0.02) but not use (p = 0.54). Respondents aged 21-30 years had better awareness of Pentazocine use compared to other age groups. Conclusion: The awareness of pentazocine use among SCD patients in the two centers studied in Lagos, Nigeria was found to be inadequate despite its wide spread use outside the clinic without clinicians' supervision. Proper education on disease condition and its management should be encouraged among SCD patients to encourage appropriate use of pentazocine, as well as other analgesics used in the management of SCD and discourage misuse.
  • Item
    Open Access
    Awareness and pattern of pentazocine use in patients with sickle cell disease in two sickle cell clinics in Lagos state, Nigeria
    (2021-08-14) Ayeni, F.A.; Ogbo, P.U.; Onwuchuluba, E.E.; Haruna, M.
    Background: Sickle cell disease (SCD) is a genetic disorder which leads to acute or chronic pain and thus requires the use of opioids and non-opioid medications. Pentazocine is a commonly used opioid among sickle cell patients for the management of moderate to severe pain. Patients understanding of the purpose and pattern of pentazocine use will encourage rational use and discourage misuse, especially outside the hospital setting. This study was set to assess the awareness and pattern of use of pentazocine among SCD patients. Methods: The study was a cross-sectional, descriptive, questionnaire-based study conducted in two sickle cell clinics in Lagos State. A pretested questionnaire based on extant literature was employed to obtain patients sociodemographic data. Data was also obtained regarding prescribed medications, as well as patients' awareness and use of pentazocine. These data were analyzed using descriptive and inferential statistics in SPSS, version 21.0. Results: Of the eighty respondents interviewed, most, 68 (85.0%) were single, 42 (52.5%) were females, and 50 (62.5%) had tertiary education. Mean age was 26.49 8.16 years. Commonly prescribed painkillers were Ibuprofen (31.4%), Paracetamol (28.9%), Diclofenac (26.9%) and Pentazocine (20.0%). Less than half, 32 (40%) were aware of pentazocine use in managing moderate to severe pain. Of these, 16 (50%) used it outside the clinic. 56.3% of those who used pentazocine outside the clinics used it because they had “unbearable pain”. There was a significant association between age and Pentazocine awareness (p = 0.02) but not use (p = 0.54). Respondents aged 21-30 years had better awareness of Pentazocine use compared to other age groups. Conclusion: The awareness of pentazocine use among SCD patients in the two centers studied in Lagos, Nigeria was found to be inadequate despite its wide spread use outside the clinic without clinicians' supervision. Proper education on disease condition and its management should be encouraged among SCD patients to encourage appropriate use of pentazocine, as well as other analgesics used in the management of SCD and discourage misuse.